VXRT Vaxart, Inc.
Price Chart
Executive Summary
Vaxart announced a $25 million at-the-market equity financing facility with Lincoln Park Capital, allowing the company to sell shares at its discretion over 24 months. The agreement provides non-dilutive flexibility but does not guarantee any funding, as Vaxart controls the timing and amount of sales.
Key Financial Metrics
Actionable Insight
Traders should monitor for future 8-Ks indicating actual drawdowns under this facility, which would signal immediate dilution. Absent such filings, this is a standby financing tool with minimal near-term impact. Watch for downward pressure on share price if draws occur during weak market conditions.
Key Facts
- Vaxart entered into a share purchase agreement (SPA) with Lincoln Park Capital Fund for up to $25 million in common stock sales over 24 months.
- Vaxart has sole discretion over the timing and amount of sales; Lincoln Park is obligated to buy at prevailing market prices with no price cap.
- No warrants, rights, or short-selling by Lincoln Park are permitted.
- A registration statement must be declared effective by the SEC before any sales can occur.
- The company issued shares to Lincoln Park as commitment consideration, though the amount is not disclosed.
Financial Impact
Up to $25 million in potential gross proceeds, subject to market conditions and Vaxart's discretion.
Risk Factors
- Potential share dilution if Vaxart draws significantly on the facility, especially in a declining stock price environment.
- Market perception of equity lines as a 'last resort' financing could negatively impact sentiment despite no immediate dilution.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276132 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
4d ago
|
DEFA14A
| $0.6000 awaiting T+5 | awaiting T+5 | — | $0.5600 (−6.67%) |
|
Jun 8, 2026
4d ago
|
DEFA14A
| $0.6200 awaiting T+5 | awaiting T+5 | — | $0.5600 (−9.68%) |
|
Jun 1, 2026
11d ago
|
DEFA14A
| $0.6300 $0.6200 | ▼ −1.59% | ▲ +1.16% | $0.5600 (−11.11%) |
|
May 20, 2026
24d ago
|
DEFA14A
| $0.6100 $0.6600 | ▲ +8.20% | ▲ +6.39% | $0.5600 (−8.20%) |
|
May 20, 2026
24d ago
|
DEFA14A
| $0.6100 $0.6600 | ▲ +8.20% | ▲ +6.39% | $0.5600 (−8.20%) |
|
May 19, 2026
24d ago
|
PREC14A
| $0.6100 $0.6600 | ▲ +8.20% | ▲ +6.39% | $0.5600 (−8.20%) |
|
May 19, 2026
24d ago
|
DEFA14A
| $0.6100 $0.6600 | ▲ +8.20% | ▲ +6.39% | $0.5600 (−8.20%) |
|
May 1, 2026
6w ago
|
Press Release
| $0.7700 $0.7400 | ▲ +3.90% | ▲ +6.24% | $0.5600 (+27.27%) |
|
Apr 21, 2026
7w ago
|
8-K
| $0.7600 $0.7800 | ▲ +2.63% | ▲ +1.55% | $0.5600 (−26.32%) |
|
Apr 17, 2026
8w ago
|
8-K
| $0.7500 $0.7200 | ▲ +4.00% | ▲ +4.55% | $0.5600 (+25.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access